LSDIF (Lucy Scientific Discovery) Cash-to-Debt: 0.10 (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lucy Scientific Discovery Cash-to-Debt?

Lucy Scientific Discovery LSDIF Cash-to-Debt is 0.10 as of Dec. 2023.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lucy Scientific Discovery's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.10.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Lucy Scientific Discovery couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Lucy Scientific Discovery's Cash-to-Debt or its related term are showing as below:

LSDIF's Cash-to-Debt is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.98
* Ranked among companies with meaningful Cash-to-Debt only.

Lucy Scientific Discovery  (OTCPK:LSDIF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lucy Scientific Discovery Cash-to-Debt Related Terms

Lucy Scientific Discovery Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Lucy Scientific Discovery's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Lucy Scientific Discovery Cash-to-Debt Chart

Lucy Scientific Discovery Annual Data
Trend Jun21 Jun22 Jun23
Cash-to-Debt
0.11 0.01 0.94

Lucy Scientific Discovery Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 1.95 0.94 0.14 0.10

LSDIF vs INQD, ZTS, VTRS: Cash-to-Debt Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucy Scientific Discovery Cash-to-Debt vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's Cash-to-Debt falls into.


Lucy Scientific Discovery Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lucy Scientific Discovery's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=1.674 / (0.399 + 1.39)
=0.94

Lucy Scientific Discovery's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=0.211 / (1.494 + 0.719)
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of 0.10 mean?
Lucy Scientific Discovery (LSDIF) has a Cash-to-Debt of 0.10 as of Dec. 2023.
Is Lucy Scientific Discovery's Cash-to-Debt too high?
Lucy Scientific Discovery's current Cash-to-Debt is 0.10. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Lucy Scientific Discovery's value of 0.10 is 89.8% below this industry median.
How does Lucy Scientific Discovery's Cash-to-Debt compare to INQD and ZTS?
Lucy Scientific Discovery's Cash-to-Debt of 0.10 can be compared against companies in the Drug Manufacturers industry. The industry median Cash-to-Debt is 0.98. Lucy Scientific Discovery's value of 0.10 is 89.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucy Scientific Discovery's current Cash-to-Debt of 0.10 is 89.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucy Scientific Discovery's current Cash-to-Debt is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucy Scientific Discovery stock overvalued right now?
Lucy Scientific Discovery (LSDIF) has a current Cash-to-Debt of 0.10. The current Cash-to-Debt is 0.10 and 89.8% below the Drug Manufacturers industry median of 0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Lucy Scientific Discovery (LSDIF), the current Cash-to-Debt is 0.10 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lucy Scientific Discovery Business Description

Address 301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6
Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.